Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women aged 18 90 years~* Subject must have a stable dialysis prescription for at least 28 days prior to start of Screening.~* Subject must have the most recent serum phosphate measurement, taken during the 28 days prior to the start of Screening, of ≥ 4.0 mg/dL and ≤ 8 mg/dL.~Exclusion Criteria:~* Subject's most recent historical pre-dialysis serum bicarbonate value within 14 days prior to the start of Screening (Visit 1) is \< 18 mg/dL.~* Subject has, in the opinion of the investigator, severe chronic lung disease and/or carbon dioxide retention.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 - PT20 400 mg tid (Type: EXPERIMENTAL): PT20 400 mg tid (1.2 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study
- Group 2 - PT20 800 mg tid (Type: EXPERIMENTAL): PT20 800 mg tid (2.4 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study
- Group 3 - PT20 1600 mg tid (Type: EXPERIMENTAL): PT20 1600 mg tid (4.8 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study
- Group 4 - PT20 3200 mg tid (Type: EXPERIMENTAL): PT20 3200 mg tid (9.6 g/day) administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study
- Group 5 - Placebo tid (Type: PLACEBO_COMPARATOR): Matched Placebo (for PT20) tid administered orally.~Dosing was initiated with the subject's first meal/snack following receipt of study medication at Visit 7 (Day 1). There was to be no change in dose administration level with respect to each cohort in this study

Based on this trial design, predict the completion outcome and termination type (if applicable).